Lancet, J., Rizzieri, D., Schiller, G., Stuart, R., Kolitz, J., Solomon, S., … Cortes, J. (2017). Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. S288–S288). Elsevier BV. https://doi.org/10.1016/j.clml.2017.07.074

Lancet, Jeffrey, David Rizzieri, Gary Schiller, Robert Stuart, Jonathan Kolitz, Scott Solomon, Laura Newell, et al. “Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study.” In Clinical Lymphoma Myeloma and Leukemia, 17:S288–S288. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.07.074.

Lancet J, Rizzieri D, Schiller G, Stuart R, Kolitz J, Solomon S, et al. Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S288–S288.

Lancet, Jeffrey, et al. “Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, Elsevier BV, 2017, pp. S288–S288. Crossref, doi:10.1016/j.clml.2017.07.074.

Lancet J, Rizzieri D, Schiller G, Stuart R, Kolitz J, Solomon S, Newell L, Erba H, Uy G, Ryan R, Chiarella M, Louie A, Cortes J. Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. S288–S288.